Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition FinancialNewsMedia - Wed Jan 24, 8:00AM CST

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 0.4850 (-1.02%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3550 (-1.50%)
ATAI : 1.9700 (+5.35%)
MNMD : 8.87 (+2.19%)
SEEL : 0.3271 (+0.43%)
CMPS : 8.25 (-1.32%)
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023 Newsfile - Wed Nov 1, 2023

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression...

CYBN : 0.3550 (-1.50%)
CYBN.NE : 0.4850 (-1.02%)
Cybin to Acquire Small Pharma Inc. Newsfile - Mon Aug 28, 2023

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders...

DMTTF : 0.1117 (-9.70%)
DMT.VN : 0.150 (-6.25%)
CYBN.NE : 0.4850 (-1.02%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 FinancialNewsMedia - Wed Jul 26, 2023

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 0.4850 (-1.02%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3550 (-1.50%)
CMPS : 8.25 (-1.32%)
SEEL : 0.3271 (+0.43%)
MNMD : 8.87 (+2.19%)
NUMIF : 0.0600 (-0.83%)
NUMI.TO : 0.0850 (+6.25%)
Cybin to Participate at the 26th Annual Milken Institute Global Conference Business Wire - Fri Apr 28, 2023

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 0.4850 (-1.02%)
CYBN : 0.3550 (-1.50%)
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy Business Wire - Wed Apr 12, 2023

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 0.4850 (-1.02%)
CYBN : 0.3550 (-1.50%)
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference Business Wire - Wed Mar 8, 2023

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that Doug...

CYBN.NE : 0.4850 (-1.02%)
CYBN : 0.3550 (-1.50%)
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder in Psychedelics Discussions Investor Brand Network - Fri Mar 3, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference;...

CYBN.NE : 0.4850 (-1.02%)
CYBN : 0.3550 (-1.50%)
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference Business Wire - Thu Mar 2, 2023

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® and The Chopra Foundation, a not-for-profit...

CYBN.NE : 0.4850 (-1.02%)
CYBN : 0.3550 (-1.50%)
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program Business Wire - Tue Feb 28, 2023

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced significant progress...

CYBN.NE : 0.4850 (-1.02%)
CYBN : 0.3550 (-1.50%)

Barchart Exclusives

Nasdaq Futures Climb on Tesla Boost, Meta Earnings in Focus Barchart - 1 hour ago
June Nasdaq 100 E-Mini futures (NQM24) are trending up +0.53% this morning as Tesla surged on new EV promises and investors looked ahead to the next round of corporate earnings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot